H.I.G.'s $1.8B Celerion Sale Highlights PE Value Creation Strategy

MIAMI, FL – June 15, 2026 – In a move that underscores both strategic acuity and the robust health of the specialized healthcare services market, H.I.G. Capital has completed the sale of Celerion Holdings, Inc. to funds affiliated with THL Partners for a striking $1.8 billion. The transaction not only marks a significant return for the Miami-based investment firm but also illuminates the powerful trends reshaping the pharmaceutical research and development pipeline. Celerion, a global leader in early-phase clinical pharmacology, now embarks on its next growth chapter, leaving behind a textbook example of private equity's value-creation playbook in action.

This sale is the capstone on a period of intense and successful exit activity for H.I.G.'s Advantage strategy. Since the fourth quarter of 2025, the firm has divested from St. Croix and United Flow Technologies, bringing the combined enterprise value of these three exits to over $4.5 billion. This string of successes is particularly noteworthy given the broader market narrative of a 'challenging exit environment,' where many private equity firms have faced pressure to generate liquidity from aging portfolios amidst stiff competition.

A Masterclass in Value Creation

H.I.G. Capital's Advantage strategy centers on identifying and investing in established, high-quality North American companies that hold a clear, defensible market position. The firm's approach goes beyond simple capital infusion, focusing on deep operational and strategic partnerships with management to accelerate growth. H.I.G. first acquired Celerion in November 2022, and in just a few years, has steered the company to a multi-billion-dollar valuation.

"The Celerion transaction is a direct reflection of what H.I.G. does best: identifying exceptional businesses in specialized markets, bringing our full operational and strategic resources to bear, and partnering closely with management to execute against a clear vision," said Matt Hankins and Rahul Vinnakota, Co-Heads of H.I.G. Advantage. "The closing is a compelling outcome for our investors and a validation of H.I.G.'s approach to value creation. We are proud of what we built with Celerion and have positioned it exceptionally well for its next chapter."

This success story validates the firm's model of targeting niche leaders and applying a disciplined growth strategy. While global healthcare private equity deal value hit a record $191 billion in 2025, the ability to execute profitable exits remains the ultimate measure of success. H.I.G. has demonstrated an ability to navigate this complex landscape, proving that even in a difficult market, well-positioned assets in non-cyclical sectors like healthcare can command premium valuations.

Celerion's Next Chapter with THL Partners

For Celerion, the acquisition by THL Partners signals a new phase of expansion. Founded in 2010 from the clinical business of MDS Pharma Services, Celerion has carved out a vital niche as a category-defining Contract Research Organization (CRO). It specializes in the critical early stages of drug development, offering a suite of services from first-in-human studies and cardiac safety assessments to complex bioanalytical laboratory services. With a global network of facilities in North America and Europe, it provides the foundational data that pharmaceutical and biotech clients need to advance their most promising compounds.

THL Partners, a firm with over three decades of investment experience in pharma services, is not a newcomer to the space. The acquisition of Celerion is being funded through its $5.6 billion flagship Fund IX and represents its third major investment in the sector in the last three years, following deals for Headlands Research and Red Nucleus. This pattern indicates a deliberate and confident strategy to build a portfolio of best-in-class pharma service providers.

THL's plans for Celerion reportedly focus on accelerating growth through both organic expansion and strategic 'tuck-in' acquisitions. The new ownership will likely fuel investments in technology and capacity, expanding Celerion's geographic reach and service capabilities to meet the relentless demand from drug developers. This strategic backing is crucial as the CRO industry itself undergoes a profound transformation.

The Evolving Landscape of Drug Development

The Celerion deal is more than just a financial transaction; it's a barometer of the entire pharmaceutical R&D ecosystem. The global CRO market, valued at over $90 billion in 2025 and projected to surpass $100 billion by 2027, is shifting from a model of transactional vendors to one of strategic co-developers. This evolution is driven by several key forces.

First, unprecedented industry consolidation continues, with large players pursuing mega-mergers and smaller, strategic bolt-on acquisitions to gain specialized capabilities. Second, the complexity of modern therapeutics, such as gene therapies and biologics, demands a level of technical and regulatory expertise that many pharma companies prefer to outsource. Small and mid-sized biotech firms, which are now responsible for a majority of FDA approvals, increasingly rely on full-service CROs to manage their clinical development programs.

Finally, technology is fundamentally reshaping how clinical trials are run. Artificial Intelligence and machine learning are moving from pilot projects to foundational infrastructure, optimizing everything from protocol design to patient recruitment. The adoption of Decentralized Clinical Trials (DCTs), or hybrid models, is becoming standard practice, reducing logistical burdens and accelerating timelines. CROs like Celerion, which operate at the intersection of clinical operations and complex data analysis, are central to this tech-driven evolution. As the industry pushes for greater efficiency and speed in bringing new medicines to patients, the strategic value of specialized, high-quality research partners will only continue to grow.